# Weineng Feng

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/weineng-feng/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,258 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 21 |
| i10-index | 36 |
| Last Known Institution | First People's Hospital of Foshan |
| OpenAlex ID | https://openalex.org/A5027373861 |
| ORCID iD | 0000-0001-5453-8605 |
| Works | 144 |

## Researcher papers

- [Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/camrelizumab-versus-placebo-in-combination-with-gemcitabine-and-cisplatin-as/)
- [Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant](https://scholariq.org/papers/ivonescimab-plus-chemotherapy-in-non-small-cell-lung-cancer-with-i-egfr-i/)
- [Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network](https://scholariq.org/papers/toward-an-expert-level-of-lung-cancer-detection-and-classification-using-a-deep/)
- [Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial](https://scholariq.org/papers/efficacy-safety-and-biomarker-analysis-of-ensartinib-in-crizotinib-resistant-alk/)
- [Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer](https://scholariq.org/papers/metabolic-reprogramming-driven-by-igf2bp3-promotes-acquired-resistance-to-egfr/)
- [Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)](https://scholariq.org/papers/efficacy-safety-and-biomarker-analysis-of-camrelizumab-in-previously-treated/)
- [The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer](https://scholariq.org/papers/the-concentration-of-erlotinib-in-the-cerebrospinal-fluid-of-patients-with-brain/)
- [Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer](https://scholariq.org/papers/reprogramming-of-tams-via-the-stat3-cd47-sirp-axis-promotes-acquired-resistance/)
- [Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial](https://scholariq.org/papers/neoadjuvant-toripalimab-combined-with-gemcitabine-and-cisplatin-in-resectable/)
- [Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial](https://scholariq.org/papers/pemetrexed-versus-gefitinib-as-a-second-line-treatment-in-advanced-nonsquamous/)
- [Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities](https://scholariq.org/papers/transcriptomic-analysis-of-transformed-small-cell-lung-cancer-from-egfr-mutated/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Neuroinflammation and Neurodegeneration Mechanisms](https://scholariq.org/topics/neuroinflammation-and-neurodegeneration-mechanisms/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [First People's Hospital of Foshan](https://scholariq.org/institutions/first-people-s-hospital-of-foshan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.